| metastatic/advanced OC (mOC) - 1st line (L1) | metastatic/advanced OC (mOC) - 2nd line (L2) | metastatic/advanced OC (mOC) - maintenance (M) | |||
| metastatic/advanced OC (mOC) - 1st line (L1) | mOC - L1 - all population | mOC - L1 - PDL1 positive | metastatic/advanced OC (mOC) - 2nd line (L2) | metastatic/advanced OC (mOC) - maintenance (M) | |
| immune chekpoint inhibitors | |||||
| anti-PD-(L)1 | |||||
| atezolizumab based treatment | |||||
| atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | AGO-OVAR 2.29/ENGOT-ov34 | ||||
| atezolizumab plus SoC | IMagyn-050 ... | IMagyn-050 ... | |||
| avelumab based treatment | |||||
| avelumab alone | JAVELIN ovarian 200 ... | ||||
| avelumab plus pegylated liposomal doxorubicin | JAVELIN ovarian 200 ... | ||||
| avelumab plus SoC | JAVELIN Ovarian 100 | ||||
| nivolumab based treatment | ATHENA-COMBO ... | ||||
| Immune checkpoint association | |||||
| nivolumab plus ipilimumab | NRG GY003 | ||||
Study type:
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
